Development of oxepanoprolinamide antibiotics for the treatment of complicated urinary tract infections
Active Grant Awarded
- Award ID
- R43AI197431
- Recipient
-
Kinvard Bio, Inc. UEI K2L6HG3N1UZ7
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $314,363
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date 30% complete
- Place of performance
- Flourtown, PA 19031, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases awarded Kinvard Bio, Inc. a grant of $314,363 on August 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds development of oxepanoprolinamide (OPP) antibiotics for complicated urinary tract infections (CUTIs). The project includes microbiological profiling of ten OPP antibiotics. The OPPs are a new class of ribosome-binding antibiotics inspired by the lincosamides. The source reports that optimization yields 300-fold improved ribosome binding compared with clindamycin and extends activity to gram-negative CUTI pathogens, including cross-resistant strains. The intended product is a non-carbapenem, non-beta-lactam/beta-lactamase-inhibitor option with intravenous dosing and oral step-down therapy. Preliminary Caco-2 studies and canine pharmacokinetic analyses suggest the OPPs have a high likelihood of oral bioavailability.
The period of performance runs from the August 3, 2026 award date to an ultimate completion date of July 31, 2027. Work is performed at Flourtown, PA 19031. The assistance type is a grant.
Description
- Abstract
- Complicated urinary tract infections (CUTI) are highly prevalent, principally gram-negative, infections worldwide that can manifest in life-threatening complications if left untreated. In an ever-increasing proportion of these infections, the failure of standard-of-care (SOC) therapy centered on beta-lactams/beta-lactam inhibitors (BL/BLI), fluoroquinolones, and trimethoprim-sulfamethoxazole has left healthcare providers with limited options for outpatient treatment or step-down from parenteral agents. To reduce reliance on last-line carbapenem antibiotics, as well as to enable outpatient treatment and earlier hospital discharges, there is a significant need for a non-carbapenem, non-BL/BLI, intravenous with oral step-down therapeutic option for the treatment of cutis. To address this critical yet unmet need, kinvard BIO is advancing a new class of highly potent ribosome-binding antibiotics termed the oxepanoprolinamides (OPPS). The OPPS are inspired by the lincosamide class of antibiotics, of which clindamycin (CLI) is the most recently approved (1970, FDA) and most widely known. While the lincosamides are primarily useful as gram-positive facing agents (and therefore less applicable to CUTI), the OPPS have been optimized to dramatically improve engagement of the bacterial ribosome (≥300-fold improved binding compared to CLI). This enhancement for the first time extends the spectrum of activity of the class to include the gram-negative pathogens responsible for CUTI, with potent activity against cross-resistant strains. Furthermore, preliminary caco-2 studies and canine pharmacokinetic analyses suggest that the OPPS have a high likelihood of oral bioavailability, following precedent from their progenitor CLI, which has 88% oral bioavailability in humans. In this project, a thorough microbiological profiling of ten OPP antibiotics against resistant CUTI isolates will be conducted, from which three finalist OPPS will be selected for further profiling in preliminary in vitro adme and in vivo pharmacokinetic studies. The three finalist OPPS will then be compared in proof-of-concept murine models of infection (neutropenic thigh infection model and ascending UTI model) using a uropathogenic escherichia coli isolate, from which one lead OPP compound will be selected for further studies to establish a full dose response profile. Through this project, we plan to progress at least one lead OPP compound toward candidate selection and preclinical development work.
Quick answers
Who received award R43AI197431?
R43AI197431 was awarded to Kinvard Bio, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on August 3, 2026.
How much is award R43AI197431 worth?
$314,363 has been obligated on R43AI197431.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award